Key statistics
As of last trade Castle Biosciences Inc (CSTL:NMQ) traded at 29.58, -17.47% below its 52-week high of 35.84, set on Nov 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 30.02 |
---|---|
High | 30.50 |
Low | 29.25 |
Bid | 29.51 |
Offer | 29.70 |
Previous close | 29.81 |
Average volume | 400.11k |
---|---|
Shares outstanding | 28.01m |
Free float | 27.11m |
P/E (TTM) | 149.11 |
Market cap | 834.90m USD |
EPS (TTM) | 0.1999 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 16:49 GMT.
More ▼
- Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
- Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
- Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
- Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
- Castle Biosciences Reports Third Quarter 2024 Results
- Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
- Castle Biosciences to Participate in Upcoming Investor Conferences
- Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
- Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
More ▼